In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Jeff Draa, Board of Directors, Tech Coast Angels
- Gabor Garai, Partner, Foley & Lardner
- Vanessa Herbert, Senior Manager, PricewaterhouseCoopers
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- Robert Mashal, M.D., President & CEO, NKT Therapeutics
- David Parrot, M.B.A., Managing Director, BMO Capital Markets Corp.
Related Insights
June 10, 2025
Foley Viewpoints
EPA to Approve Texas use of CO2 Sequestration Wells
Today, the EPA took an important step in allowing Texas to issue permits for Class VI wells within the state. Class VI wells are used for…
June 10, 2025
Foley Viewpoints
Supreme Court Rejects Minimum Contacts Requirement to Subject Foreign States to Suits in the U.S. Under FSIA
On June 5, 2025, in a unanimous decision authored by Justice Alito, the United States Supreme Court held that the Foreign Sovereign Immunities Act of 1976 (FSIA), 28 U.S.C. §§1330, 1602 et seq., does not require a plaintiff to prove a foreign state has made “minimum contacts” with the United States sufficient to satisfy the personal jurisdiction test set forth in International Shoe Co. v. Washington, 326 U.S. 310, 316 (1945).
June 10, 2025
Foley Ignite
Investor Insights: An Overview of PitchBook’s H1 2025 VC Tech Survey
Having done a deep dive into PitchBook’s H1 2025 VC Tech Survey, not to mention living and breathing the state of venture with my clients who are in market for capital, I wanted to share my thoughts about how investors appear to be recalibrating their approach to technology startups.